Kwan Ho Tang

机构：AstraZeneca (South Korea), AstraZeneca (Netherlands), AstraZeneca (Brazil), AstraZeneca (Japan), AstraZeneca (United States) · ORCID：0000-0001-7729-5159

发表论文 123 篇 · 总被引 3964 次 · h-index 18

代表论文

• Cellular adaptation to cancer therapy along a resistance continuum (2024 · Nature · 被引 174)
• ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib (2025 · JCO Precision Oncology · 被引 10)
• ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib (2026 · Cancer Discovery · 被引 7)
• Hydroxychloroquine prevents resistance and potentiates the antitumor effect of SHP2 inhibition in NF1-associated malignant peripheral nerve sheath tumors (2024 · Proceedings of the National Academy of Sciences · 被引 7)
• Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report (2025 · Journal of Thoracic Oncology · 被引 5)
• Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD (2026 · Lung Cancer · 被引 2)